The FDA last week approved Eli Lilly and Co’s new...

...migraine drug, Emgality. While the injectable will theoretically be a competitor to Amgen’s Aimovig, Lilly plans to sell the drug for the same price, $575 per month. Aimovig currently holds preferred tier status, with step therapy or prior authorization, for 22% of covered lives, and is not covered for 35% of lives. Another migraine therapy similar to both Aimovig and Emgality, Teva Pharmaceutical’s AJOVY, was also approved by the FDA in September.